Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Jefferam1on Sep 05, 2018 9:56am
138 Views
Post# 28564669

RE:ANTIBE LONGs rewarded for patience!

RE:ANTIBE LONGs rewarded for patience!
SergeantSanderz wrote:
  • The $13 mil upfront along with leftover cash (after completion of FINAL Phase 2, parts 1 and 2) and some incoming cash from the last warrants may add up to be enough money to fully fund Phase 3.  WOW!  A strong place to be in!  We may be ready for our SK partner to commence sales by late 2020!



Hold the horses SergeantSanders, 
Don't get me wrong this is great news but you post is missleading (hopefully no intentionally).
1.3 Million upfront (not 13 Million).
$13 million in non-dilutive development and commercial milestone payments
That means there will be milestone payments which will include payments in Phase 3 and comercialization so they are not getting the full 13 million till then and probably the majority of it will be in the later phases.

Plus Antibe will have to do 2 Phase 3 trials which will be 10-25 Million each (I'm guessing here, don't have the numbers but they are expensive).  Antibe does not and will not have the money for Phase 3. But in the end that doesn't matter, there business plan is to partner prior to Phase 3. So they don't need the money to get there. All they need is the money to get to the end of phase 2 trials and probably another 12 months after to buy time for partnership. This deal should get them near that now and with the milestone payments probably does get them there.

This might give them the money to speedup the pipepline drugs too. And if citagenix stops the bleeding and gets even cashflow this is shaping up nicely.



Bullboard Posts